NeurogesX
Innovative therapies for chronic peripheral neuropathic pain.
Innovative therapies for chronic peripheral neuropathic pain.
NeurogesX is a biopharmaceutical company with a focus on developing and commercializing innovative therapies for pain management, particularly chronic peripheral neuropathic pain. The company's flagship product, NGX-4010, is a dermal patch infused with capsaicin, designed to alleviate pain associated with peripheral neuropathic conditions such as postherpetic neuralgia (PHN), painful HIV-distal sensory polyneuropathy (HIV-DSP), and painful diabetic neuropathy (PDN). In addition to NGX-4010, NeurogesX is also working on NGX-1998, a non-patch liquid formulation of synthetic capsaicin, and an opioid analgesic for managing other chronic pain conditions, including cancer pain. The company, founded in 1998 as Advanced Analgesics, Inc., rebranded as NeurogesX, Inc. in 2000. Based in San Mateo, California, NeurogesX received a $975.00K post-IPO equity investment on 29 March 2012. The company operates within the Biotechnology and Medical Devices industries.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Post-IPO Equity | $975.00K | - | 29 Mar 2012 | |
| Post-IPO Equity | $3.00M | - | 02 Feb 2012 | |
| Post-IPO Equity | $20.21M | - | 03 Aug 2011 | |
| Post-IPO Equity | $25.00M | 1 |
|
09 Jan 2008 |
| Series D | $20.00M | 6 |
|
01 Dec 2005 |
No recent news or press coverage available for NeurogesX.
We care about your data, and we'd love to use cookies make your experience better.
